University of Leeds – BioScreening Technology Group (BSTG)

siRNA is a powerful tool that identifies the function of genes by silencing their expression and examining the phenotypic consequences.  At the BSTG we primarily perform cell based whole or part-genome siRNA screens to individually silence genes in the human or mouse genome to identify genes that impact on cellular pathways and human disease. To achieve this we develop specific end-point phenotypic assays (based on high content microscopy or fluorimetery) to assess the consequences of knockdown and identify genes associated with the phenotype or disease of interest.  Similarly we perform miRNA screens. Our final area of expertise is in performing cell based high-throughput small molecule screens to identify novel therapeutics for treatment of human and animal disease.


Show full profile

Principal Disease Indication(s)

All human diseases


Platform(s)

Genome-wide human and mouse RNAi, miRNA inhibitors and mimics, small molecule screening, drug repurposing


Technology(ies):

HCI, MPA, HTS plate reader


Funding sources:

University of Leeds, UK government, charities, European Commission


Personnel:

2


Number of Screens / year (any size):

5-8


Medicinal Chemistry Follow-up:

Yes


Contact Details

Dr Jacquelyn Bond and Dr Julie Higgins

Phone: +44 (0)113 343 7099
leeds.ac.uk

Contact Form

To contact us, please fill in the form below


Getting there

Address: University of Leeds, Leeds, West Yorkshire LS2 9JT, UK
X
- Enter Your Location -
- or -